vimarsana.com

Latest Breaking News On - Valeria fisher - Page 1 : vimarsana.com

Vivoryon Therapeutics N V Reports Q1 2024 Financial Results and New Data Reinforcing Strategic Focus in Kidney Disease

Vivoryon Therapeutics N V Reports Q1 2024 Financial Results and New Data Reinforcing Strategic Focus in Kidney Disease
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Noord hollandKugan sathiyanandarajahDanne doeringValeria fisherManuela baderFrank weberMorten asser karsdalCorporate development updatesTrophic communicationsNew data reinforcing strategic focusKidney diseaseEuronext amsterdamNon executive directorsChief financial officerChief strategyInvestor relations

Vivoryon Therapeutics N V Reports Q1 2024 Financial Results And New Data Reinforcing Strategic Focus In Kidney Disease

Noord hollandKugan sathiyanandarajahFrank weberManuela baderMorten asser karsdalValeria fisherDanne doeringTrophic communicationsCorporate development updatesNew data reinforcing strategic focusKidney diseaseEuronext amsterdamPost period updatesNon executive directorsChief financial officerChief strategy

Vivoryon Therapeutics N V to Report Q1 2024 Financial Results and Operational Progress on May 23, 2024

Vivoryon Therapeutics N.V. to Report Q1 2024 Financial Results and Operational Progress on May 23, 2024 Halle / Munich, Germany, May 15, 2024 - Vivoryon Therapeutics N.V. , a clinical stage.

Manuela baderValeria fisherTrophic communicationsOperational progressEuronext amsterdam

Vivoryon Therapeutics N V to Hold its 2024 Annual General Meeting on June 21, 2024

Vivoryon Therapeutics N V to Hold its 2024 Annual General Meeting on June 21, 2024
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Noord hollandManuela baderValeria fisherTrophic communicationsGeneral meetingEuronext amsterdam

Vivoryon Therapeutics N V Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates

24.04.2024 - Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates In-depth analysis of VIVIAD Phase 2b results is ongoing, including pre-specified and exploratory endpoints; findings to date .

Noord hollandMorten asser karsdalFrank weberPenelope belnapKugan sathiyanandarajahValeria fisherUlrich dauerDanne doeringCompany annualInternational accounting standards boardSimcere pharmaceutical group ltdCorporate development updatesEuropean unionVaroglutamstat clinical programTrophic communicationsInternational financial reporting standards

vimarsana © 2020. All Rights Reserved.